Viewing nowCombinationLinagliptin/Metformin Duo Tablets 2.5/1000 mg
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albozen Korea Co., Ltd.

MFDS item code 201902609 · Approved 2019.04.25 · Insurance code 652607290
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood sugar control for patients with type 2 diabetes, in conjunction with diet and exercise therapy. Particularly, Linagliptin and Metformin work together to effectively manage blood glucose levels. This helps to improve blood sugar management and contributes to the prevention of diabetes-related complications. Therefore, it is used to enhance blood sugar control in patients with type 2 diabetes.
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Patients whose blood glucose is not adequately controlled with metformin monotherapy: The initial dose of this medication should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's previous metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should start at their previous doses of linagliptin and metformin. 4. Patients whose blood glucose is not adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medication is administered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's previous metformin dose. When this medication is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with other oral antihyperglycemic agents. Any change in the treatment regimen for type 2 diabetes may result in a change in blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Use This Medication).
This medication is primarily used for diabetes treatment and helps in controlling blood sugar levels. However, this medication can cause serious side effects such as lactic acidosis, so patients with poor kidney function or liver issues should not use it. Patients with type 1 diabetes, a specific form of diabetes, or diabetic ketoacidosis should also not take this medication. Patients with severely decreased heart or lung function, those in acute infections, severe trauma, or in shock should avoid using this medication. It is also advised that pregnant or breastfeeding women do not take this medication for safety. When using this medication with other antidiabetic agents, there is a risk of hypoglycemia, so caution is required, especially if used in combination with insulin or sulfonylureas, as dosage adjustments may be necessary. Elderly patients with decreased kidney function or those taking medications that affect the kidneys should regularly undergo kidney function tests and adjust usage of this medication as needed. Additionally, this medication can cause rare side effects such as acute pancreatitis or bullous pemphigoid, so if abdominal pain or skin abnormalities occur while taking it, immediate medical consultation is necessary. This medication can lower vitamin B12 levels, so it is advisable to regularly check vitamin B12 levels during long-term use. If iodine contrast agents are used during radiological examinations, this medication should be temporarily discontinued before and after the examination due to the risk of decreased kidney function and lactic acidosis. Patients undergoing surgery should also stop this medication 48 hours prior to surgery and resume only after confirming recovery of kidney function post-surgery. In case of planning a pregnancy or if pregnant, insulin therapy is recommended instead of this medication, and this medication is also safe to avoid during breastfeeding. Use of this medication is not recommended in children under 10 years old, and safety and efficacy have not been adequately confirmed in adolescents over 10 years old. There have been no studies conducted on the effects of this medication on driving or operating machinery, so caution is needed. In cases of overdose, serious side effects such as lactic acidosis can occur, so immediate medical attention should be sought.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. Also, it is best to store it at room temperature between 1 and 30 degrees Celsius. Storing it this way helps to maintain the effectiveness of the medication.
Light pink, bilaterally convex, oval film-coated tablet
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Albozen Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.